New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
10:01 EDTMDU, PRO, PL, MOH, AHS, ZMH, WU, PM, GRPN, BPL, IRWD, UTIW, NNA, CMCSAOn the Fly: Analyst Upgrade Summary
Today’s noteworthy upgrades include: AMN Healthcare (AHS) upgraded to Buy from Neutral at SunTrust... Avon Products (AVP) upgraded to Neutral from Sell at UBS... Comcast (CMCSA) upgraded to Outperform from Neutral at Credit Suisse... Groupon (GRPN) upgraded to Buy from Neutral at Sterne Agee... Molina Healthcare (MOH) upgraded to Buy from Neutral at BofA/Merrill... Navios Acquisition (NNA) upgraded to Outperform from Market Perform at Wells Fargo... Philip Morris (PM) upgraded to Neutral from Reduce at Nomura... Protective Life (PL) upgraded to Neutral from Underperform at BofA/Merrill... UTi Worldwide (UTIW) upgraded to Buy from Hold at Jefferies... Western Union (WU) upgraded to Underperform from Sell at CLSA... Avon Products (AVP) upgraded to Buy from Neutral at B. Riley Caris... PROS (PRO) upgraded to Buy from Hold at Craig-Hallum... Western Union (WU) upgraded to Neutral from Sell at Compass Point... Ironwood (IRWD) upgraded to Neutral from Underperform at Wedbush... Zimmer (ZMH) upgraded to Buy from Hold at Argus... Buckeye Partners (BPL) upgraded to Buy from Hold at Argus... MDU Resources (MDU) upgraded to Buy from Hold at Williams Capital.
News For AHS;CMCSA;GRPN;MOH;NNA;PM;PL;UTIW;WU;PRO;IRWD;ZMH;MDU;BPL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
June 19, 2015
11:52 EDTCMCSATime Warner Cable CEO says Ralph Roberts a 'pioneer, visionary, role model'
Subscribe for More Information
10:37 EDTCMCSAComcast announces death of founder and Chairman Emeritus Ralph Roberts
Subscribe for More Information
10:09 EDTMOHFly Watch: Supreme Court may release key ACA decision soon
Subscribe for More Information
09:22 EDTNNANavios Acquisition announces sale of to VLCCs to Navios Maritime Midstream
Navios Maritime Acquisition (NNA) announced the sale and delivery of the C. Dream, a 2000-built VLCC of 298,570 dwt, and the Nave Celeste, a 2003-built VLCC of 298,717 dwt, to Navios Maritime Midstream Partners (NAP) for a total consideration of $100.0M, payable in the form of $73.0M in cash and $27.0M in a new class of Series A Subordinated Units.
June 18, 2015
17:04 EDTCMCSAComcast files to sell 2.66M shares of Class A common stock for holders
Subscribe for More Information
13:31 EDTCMCSANBC names Holt anchor of Nightly News, Williams apologizes
Subscribe for More Information
07:51 EDTMOHIncrease in 3R backstop most positive for Humana, says Leerink
Subscribe for More Information
06:16 EDTCMCSALester Holt expected to be named permanent 'Nightly News' anchor, WSJ reports
Brian Williams will stay with NBC in an undisclosed role and Comcast is expected to make Lester Holt permanent anchor of "Nightly News," a source tells The Wall Street Journal. Williams was taken off the air earlier this year following allegations he exaggerated a story from his days covering the war in Iraq in 2003. Reference Link
June 17, 2015
17:40 EDTCMCSAComcast 'isn't interested' in T-Mobile, Washington Post says
Subscribe for More Information
11:28 EDTIRWDJPMorgan reiterates Overweight on Ironwood amid selloff
Subscribe for More Information
11:27 EDTIRWDSynergy's plecanatide not yet a threat to Ironwood's Linzess, says BofA/Merrill
Subscribe for More Information
10:44 EDTIRWDSynergy a potential takeover target after constipation drug data
The shares of Synergy Pharmaceuticals (SGYP) are rallying after the company announced that its chronic constipation treatment had met its primary endpoint in a Phase 3 clinical trial. Research firm Canaccord has previously identified Synergy as a potential takeover target and a Bloomberg report said the company had hired advisers to explor a potential sale. WHAT'S NEW: Synergy reported this morning that the 3 mg and 6 mg versions of its anti-constipation drug, plecanatide, had met their primary endpoint in a Phase III trial. Specifically, a statistically significant percentage of patients taking both versions of the drugs responded favorably, based on criteria that the FDA uses to determine approval of chronic constipation treatments, the company stated. Plecanatide was safe and well tolerated at both dose, and the results were positive, the company reported. "These results strengthen our belief that plecanatide has the potential to not only effectively treat constipation but with a durability and tolerability profile that is ideal for chronic use," said Synergy CEO Gary Jacob. "We look forward to the results of our second pivotal trial in the coming weeks," he added. WHAT'S NOTABLE: In a note to investors on May 22, Canaccord analyst Corey Davis initiated coverage of Synergy with a Buy rating. There is "a high likelihood" that data from the company's four Phase III trials due to be conducted over the next year will be positive and the company would be an attractive takeover target if its Phase III data is positive, Jacobs wrote. The analyst placed an $11 price target on the shares. Meanwhile, in March, Bloomberg reported that Synergy was talking to advisers about potentially selling the company after its competitor, Salix Pharmaceuticals, had agreed to be acquired by Valeant Pharmaceuticals (VRX). After the company reported the trial results today, its CEO told Bloomberg that "all options are on the table." IRONWOOD: The shares of Ironwood (IRWD), whose Linzess drug also treats chronic constipation, are falling today following Synergy's data readout. Canaccord's Davis had said that the diarrhea rate of patients taking Synergy's plecanatide had to come in at 10% or lower for the drug to achieve "best differentiation" versus Linzess. Patients taking the 3 mg dose of plecanatide had a diarrhea rate of 5.5%, while 5.9% of those taking the 6 mg dose experienced diarrhea, Synergy reported. Linzess is co-marketed by Ironwood and Forest Pharmaceuticals, a unit of Allergan (AGN). PRICE ACTION: In morning trading, Synergy surged 45% to $6.74, while Ironwood slid fractionally to $12.16.
10:22 EDTCMCSAComcast not interested in pursuing T-Mobile, DJ says
Subscribe for More Information
10:13 EDTCMCSADeutsche Telekom shopping T-Mobile to Comcast, FT reports
Subscribe for More Information
10:00 EDTMOHOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with an Overweight at Piper Jaffray... Arista Networks (ANET) initiated with a Buy at Sterne Agee CRT... Astec (ASTE) initiated with a Buy at Maxim... Bristol-Myers (BMY) initiated with an Underweight at Piper Jaffray... Community Healthcare (CHCT) initiated with an Outperform at Oppenheimer... Eli Lilly (LLY) initiated with an Overweight at Piper Jaffray... Fitbit (FIT) initiated with a Buy ahead of IPO at Dougherty... Hortonworks (HDP) initiated with a Buy at Mizuho... II-VI (IIVI) initiated with a Buy at Benchmark Co.... J Sainsbury (JSAIY) initiated with an Underperform at Credit Suisse... McDermott (MDR) initiated with an Outperform at Cowen... Merck (MRK) initiated with a Neutral at Piper Jaffray... Molina Healthcare (MOH) initiated with a Buy at UBS... Pacific DataVision (PDVW) initiated with a Buy at Canaccord... Pfizer (PFE) initiated with an Overweight at Piper Jaffray... Quest Resource (QRHC) initiated with a Buy at Roth Capital... Regional Management (RM) initiated with a Buy at Janney Capital... Rofin-Sinar (RSTI) initiated with a Buy at Benchmark Co.... Salesforce (CRM) initiated with a Neutral at Exane BNP Paribas... Sprouts Farmers Markets (SFM) initiated with a Neutral at Cleveland Research... Tesco (TSCDY) initiated with an Underperform at Credit Suisse... WM Morrison (MRWSY) initiated with a Neutral at Credit Suisse... WWE (WWE) initiated with a Buy at BTIG... World Acceptance (WRLD) initiated with a Buy at Janney Capital... Zafgen (ZFGN) initiated with a Buy at SunTrust.
09:25 EDTIRWDIronwood slips after Synergy announces data on constipation drug
Shares of Ironwood (IRWD) are lower in pre-market trading after Synergy Pharmaceuticals (SGYP) announced top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses in adult patients with chronic idiopathic constipation. Plecanatide was safe and well tolerated at both doses, Synergy said, noting that the most common adverse event was diarrhea, which occurred in 5.9% of patients in 3.0 mg and 5.5% of patients in 6.0 mg dose groups. Ironwood’s competing Linzess drug had a 16% diarrhea rate for CIC patients, according to its FDA label. Linzess is co-marketed by Ironwood and Forest Pharmaceuticals, a unit of Allergan (AGN). Ironwood shares are down 45c, or 3.7%, to $11.75 in pre-market trading.
09:16 EDTNNANavios Acquisition to sell two VLCCs to Navios Maritime Midstream for $100M
Subscribe for More Information
07:26 EDTCMCSADeutsche Telekom, Comcast in talks over possible T-Mobile sale, Reuters says
Subscribe for More Information
06:20 EDTCMCSAHulu luring content producers from Netflix, WSJ reports
Subscribe for More Information
05:35 EDTMOHMolina Healthcare initiated with a Buy at UBS
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use